Alternative signalling mechanisms to mediate Braf-Inhibitor resistance in isogenic primary and metastatic melanoma.

e21045Background: Activating Braf oncogenic mutations occur in up to 60% of malignant melanomas. Braf inhibitors such as Vemurafenib/Dabrafenib have demonstrated clinical benefit but responses are ...